Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
The diagnosis of Alzheimer's disease can be improved by the use of biological measures.
Biomarkers of functional impairment, neuronal loss, and protein deposition that can be …
Biomarkers of functional impairment, neuronal loss, and protein deposition that can be …
Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches
Progressive supranuclear palsy (PSP), previously believed to be a common cause of
atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes …
atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes …
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease
The recent development of tau-specific positron emission tomography (PET) tracers enables
in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease …
in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease …
Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults
Importance Mounting evidence suggests that sex differences exist in the pathologic
trajectory of Alzheimer disease. Previous literature shows elevated levels of cerebrospinal …
trajectory of Alzheimer disease. Previous literature shows elevated levels of cerebrospinal …
Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression
Studies have shown that women on the Alzheimer's disease (AD) continuum have more
pathological tau in the brain and cerebrospinal fluid (CSF), than men. Some studies have …
pathological tau in the brain and cerebrospinal fluid (CSF), than men. Some studies have …
Comparing plasma phospho tau, total tau, and phospho tau–total tau ratio as acute and chronic traumatic brain injury biomarkers
R Rubenstein, B Chang, JK Yue, A Chiu… - JAMA …, 2017 - jamanetwork.com
Importance Annually in the United States, at least 3.5 million people seek medical attention
for traumatic brain injury (TBI). The development of therapies for TBI is limited by the …
for traumatic brain injury (TBI). The development of therapies for TBI is limited by the …
Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be?
JL Whitwell, GU Höglinger, A Antonini… - Movement …, 2017 - Wiley Online Library
ABSTRACT PSP is a pathologically defined neurodegenerative tauopathy with a variety of
clinical presentations including typical Richardson's syndrome and other variant PSP …
clinical presentations including typical Richardson's syndrome and other variant PSP …
Brain imaging of neurovascular dysfunction in Alzheimer's disease
A Montagne, DA Nation, J Pa, MD Sweeney… - Acta …, 2016 - Springer
Neurovascular dysfunction, including blood–brain barrier (BBB) breakdown and cerebral
blood flow (CBF) dysregulation and reduction, are increasingly recognized to contribute to …
blood flow (CBF) dysregulation and reduction, are increasingly recognized to contribute to …
AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies
K Kantarci, VJ Lowe, BF Boeve, ML Senjem… - Annals of …, 2017 - Wiley Online Library
Objective Patients with probable dementia with Lewy bodies (DLB) often have Alzheimer's
disease (AD)‐related pathology. Our objective was to determine the pattern of positron …
disease (AD)‐related pathology. Our objective was to determine the pattern of positron …
18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
Tau positron emission tomography ligands provide the novel possibility to image tau
pathology in vivo. However, little is known about how in vivo brain uptake of tau positron …
pathology in vivo. However, little is known about how in vivo brain uptake of tau positron …